Ajax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification –
– AJ1-11095 is currently in a Phase 1 clinical trial in patients with myelofibrosis, previously treated with a type I JAK2 inhibitor –
Excerpt from the Press Release:
NEW YORK and CAMBRIDGE, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) — Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the presentation of preclinical data for AJ1-11095, the company’s first-in-class type II JAK2 inhibitor that is currently in a Phase 1 trial in patients with myelofibrosis who have previously been treated with a type I JAK2 inhibitor and have either not responded or have lost response (NCT identifier: NCT06343805). The preclinical results demonstrate the superior efficacy profile of AJ1-11095, compared to ruxolitinib, one of the four FDA-approved type I JAK2 inhibitors, in well validated MPN models. The poster is being presented at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, FL, in a session on December 6th, 2025, at 5:30-7:30 p.m. EST in the West Halls B3-B4 (Presentation #1983.)
The poster entitled “AJ1-11095, a potent and highly selective type II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)” includes the following preclinical data highlights:
- In ruxolitinib-persistent JAK2 mutant cells, AJ1-11095 restored the inhibition of JAK/STAT signaling, supporting the ability to overcome type I JAK2 inhibitor mediated persistence.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?